Trial Profile

A Phase 1b-2, Multicenter, Trial to Evaluate the Efficacy, Safety, Pharmacokintetics, and Pharmacodynamics of REC-4881 in Patients with Familial Adenomatous Polyposis (FAP)

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC 4881 (Primary)
Indications Familial adenomatous polyposis
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms TUPELO
Sponsors Recursion Pharmaceuticals

Most Recent Events

08 Dec 2025 Results presented in the Recursion Pharmaceuticals Media Release.
05 Nov 2025 According to a Recursion Pharmaceuticals media release, Additional data in FAP from the Phase 2TUPELO study expected in December 2025.
05 Aug 2025 According to a Recursion Pharmaceuticals media release, an additional data in FAP from TUPELO expected in 2H25

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com